Gastrointestinal Cancer
See how Bayer is investigating gastrointestinal cancer across the pipeline
Follow the connections from areas of research to investigational compounds and the clinical trials evaluating them.
Gastrointestinal Cancer Overview
Bayer’s gastrointestinal cancer research spans multiple molecular targets and scientific approaches that may play a role across colorectal, esophageal, and pancreatic cancers. The current pipeline includes programs targeting KRAS-G12D, SOS1, WRN, PRMT5, and RAS-PI3Kα.
Together, these programs represent multiple scientific approaches being investigated across gastrointestinal cancers, connecting areas of research with compounds in development and their related clinical trials.
5 investigational compounds
4 areas of research
6 clinical trials
Clinical Trials
Tumor Type(s) | Phase | Status | Description | NCT Number |
|---|---|---|---|---|
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic) | I | Now Enrolling | A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic) | I | Now Enrolling | Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRAS-G12C-mutated Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Esophageal, Pancreatic) | I | Now Enrolling | A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS-G12D Mutation | |
Solid Tumors, Gastrointestinal Cancer (Colorectal) | I | Now Enrolling | A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | |
Solid Tumors, Gastrointestinal Cancer (Pancreatic) | I, II | Now Enrolling | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors | |
Gastrointestinal Cancer (Colorectal) | II | Now Enrolling | A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum |
Bayer’s Oncology Pipeline Brochure
Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.
The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.
KRAS-G12C, Kirsten rat sarcoma viral oncogene homolog with a glycine-to-cysteine substitution at codon 12; KRAS-G12D, Kirsten rat sarcoma viral oncogene homolog with a glycine-to-aspartic acid substitution at codon 12; MAPK, mitogen-activated protein kinase; MTAP, methylthioadenosine phosphorylase; PI3Kα, phosphatidylinositol 3-kinase alpha; PRMT5, protein arginine methyltransferase 5; RAS, rat sarcoma; SOS1, son of sevenless homolog 1; WRN, Werner syndrome protein.